Results 181 to 190 of about 36,129 (239)

HDX-MS Detects Steric Protection and Trimeric Compaction of TNFα after It Binds Receptors or Antibodies. [PDF]

open access: yesACS Omega
Haynes CA   +7 more
europepmc   +1 more source

Infliximab for Refractory Diffuse Sclerosing Osteomyelitis of the Mandible Associated With Ulcerative Colitis: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 11, November 2026.
ABSTRACT Diffuse sclerosing osteomyelitis (DSO) of the mandible is a chronic nonbacterial inflammatory bone disease. We report a 65‐year‐old woman with ulcerative colitis who presented with swelling and pain of the left mandible. The lesion was refractory to tooth extraction, prolonged antibiotics, and nonsteroidal anti‐inflammatory drugs.
Mayumi Yao   +5 more
wiley   +1 more source

Window of Opportunity and Predictors of Sustained Remission in Patients with Hidradenitis Suppurativa Treated with Adalimumab: A 540-Patient Cohort Study. [PDF]

open access: yesDermatol Ther (Heidelb)
Vilarrasa E   +16 more
europepmc   +1 more source

Switching From Originator to Biosimilar Infliximab in Pediatric Inflammatory Bowel Disease: A Systematic Review and Meta‐Analysis

open access: yesJCC Plus, Volume 1, Issue 6, November 2026.
In this meta‐analysis of eight studies (508 children with inflammatory bowel disease), switching from originator to biosimilar infliximab preserved clinical remission, drug exposure, and immunogenicity, with high treatment persistence and no signal of efficacy or safety loss. Biosimilar switching appears a safe, effective option in pediatric IBD.
Douglas Amaral da Silva Menegazzo Miotto   +4 more
wiley   +1 more source

Deficiency of adenosine deaminase 2 in paediatric patients: a case series from Ireland. [PDF]

open access: yesFront Pediatr
Almubarak R   +4 more
europepmc   +1 more source

Protocol for the Therapy Personalisation Using Multiomic Analyses in Inflammatory Bowel Disease (THAMES‐IBD) Study

open access: yesJCC Plus, Volume 1, Issue 6, November 2026.
ABSTRACT Background Despite an expanding repertoire of advanced therapies for inflammatory bowel disease (IBD), treatment outcomes remain suboptimal, with only 30%–40% of patients achieving sustained remission. Emerging evidence indicates that therapeutic outcomes are shaped by complex interactions between host immune pathways, the gut microbiome and ...
John P. Thomas   +14 more
wiley   +1 more source

Establishing Stakeholder Priorities for Development of a Multi‐Arm Multi‐Stage Platform Trial in Crohn's Disease

open access: yesJCC Plus, Volume 1, Issue 6, November 2026.
An international modified Delphi study identified stakeholder consensus on population, interventions, comparators and outcomes to inform development of a future multi‐arm, multi‐stage adaptive platform trial for Crohn's disease. ABSTRACT Background and Aims The expanding range of advanced therapies for Crohn's disease (CD) has increased complexity in ...
Shellie J. Radford   +15 more
wiley   +1 more source

Management Considerations for Patients with Hidradenitis Suppurativa and Lupus Spectrum Disease: A Narrative Review. [PDF]

open access: yesDermatol Ther (Heidelb)
Chung CS   +5 more
europepmc   +1 more source

Clinical Decision‐Making During Monitoring Episodes in Advanced Therapy Management for Inflammatory Bowel Disease: A National Nurse‐Led Service Evaluation

open access: yesJCC Plus, Volume 1, Issue 6, November 2026.
This national, multisite, nurse‐led evaluation highlights practice patterns across UK IBD centres, revealing reliance on reactive flare‐driven treatment modification. Balancing this with structured proactive surveillance and therapeutic drug monitoring aligns with treat‐to‐target principles and supports safer advanced therapy care across diverse ...
Vida Cairnes   +18 more
wiley   +1 more source

Home - About - Disclaimer - Privacy